We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 11, 2020

Ablative Stereotactic Radiotherapy for Oligometastatic Cancer

JAMA Oncology

 

Additional Info

JAMA Oncology
Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-Analysis
JAMA Oncol 2020 Nov 25;[EPub Ahead of Print], EJ Lehrer, R Singh, M Wang, VM Chinchilli, DM Trifiletti, P Ost, S Siva, MB Meng, L Tchelebi, NG Zaorsky

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading